Company intelligence / Profile preview

GammaDelta Therapeutics

London, England, United Kingdomtakeda.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Advanced a first program into Phase 1 clinical trials for cancer using allogeneic γδ T cells. The company’s approach was considered differentiated and promising for both solid and blood cancers. No detailed efficacy results publicly available as of acquisition.

Therapeutic areas: OncologyImmunology
Modalities: Allogeneic cell therapies based on gamma delta (γδ) T cells, specifically Vδ1+ T cells
Industry: Biotech

Drug pipeline

1 asset

GDX012

Phase 1

Indications: Acute myeloid leukemia

Partnerships

Takeda Pharmaceutical Company Limited—strategic collaboration and eventual acquirer.Abingworth LLP—major investor and collaborator.

Beyond the preview

Go deeper on GammaDelta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GammaDelta Therapeutics.

Explore the full profile